White Paper

Single-Use Process Platforms Help Biomanufacturers Reduce Costs

By Miriam Monge

BSC_Outsource_8857

There are many new challenges facing those involved in the manufacture of biopharmaceuticals. Whereas in the past, overall process efficiency was sometimes treated as an afterthought as companies tried to get to market as quickly as  possible, the production costs of biophar-maceuticals are now, receiving greater attention which is spurring interest in continuous bioprocessing. The loss of  patent protection from blockbuster drugs is creating a market for biosimilars in which being able to compete effectively requires low prices underpinned by low manufacturing costs.

Enhanced flexibility and reduced operating costs are being achieved through the  widespread adoption of single-use  technology either as part of completely single-use processes or as hybrid solutions. However, questions around suitable stan-dards for product contact plastics continue to be debated within industry forums.  Greater assurance can be provided to  regulators that products are manufactured by well controlled and characterized  processes due to advances in process  analytical technologies and enhanced  QbD regulatory submissions.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: